Published in Eur J Haematol on October 01, 1988
Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. Br J Cancer (1993) 0.79
Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma. Haematologica (2010) 0.75
A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry (1983) 6.38
Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards. Cytometry (1983) 2.32
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood (1981) 1.68
Limits of detection of nuclear DNA abnormalities by flow cytometric DNA analysis. Results obtained by a set of methods for sample-storage, staining and internal standardization. Cytometry (1983) 1.56
Long-term storage of samples for flow cytometric DNA analysis. Cytometry (1983) 1.36
Treatment of small-cell carcinoma of the lung monitored by sequential flow cytometric DNA analysis. Cancer Res (1982) 1.18
Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet (1987) 1.15
Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. Cancer Res (1980) 1.05
Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Acta Pathol Microbiol Scand A (1973) 1.02
A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer (1983) 1.02
Membrane transport of anthracyclines. Pharmacol Ther (1982) 1.00
Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med (1988) 0.99
Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF. Eur J Clin Invest (1992) 0.98
Follicular low-grade non-Hodgkin's lymphoma: long-term outcome with or without tumor progression. Eur J Haematol (1989) 0.98
Lymphoblastic lymphoma: a clinicopathologic study of 95 patients. Cancer (1981) 0.94
Mechanism of resistance to anthracyclines and vinca alkaloids. Prog Clin Biol Res (1983) 0.93
Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer (1988) 0.91
Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113. Leuk Res (1979) 0.91
Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan). Cancer (1980) 0.89
Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo. A new treatment principle. Cancer Treat Rev (1984) 0.89
Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells. Cancer Chemother Pharmacol (1987) 0.88
Synchronization of the human promyelocytic cell line HL 60 by thymidine. Cell Tissue Kinet (1986) 0.87
Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol (1985) 0.86
PHASE I clinical trial of an oral solution of VP-16-213. Cancer Treat Rep (1976) 0.84
Occurrence of human T cell lymphotropic virus (type I) antibodies in cutaneous T cell lymphoma. J Am Acad Dermatol (1986) 0.83
Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors. Cancer Chemother Rep (1972) 0.83
Thyroid function in malignant lymphoma. Acta Med Scand (1977) 0.83
Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Cancer Chemother Pharmacol (1992) 0.83
Radiotherapy versus combined modality treatment of stage I and II Hodgkin's disease. Cancer Treat Rep (1982) 0.83
Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor. Eur J Haematol (1993) 0.82
Fatal hepatitis following irradiation and vincristine. Acta Med Scand (1982) 0.82
A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas. Leuk Lymphoma (1992) 0.81
The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review. Recent Results Cancer Res (1980) 0.81
Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep (1982) 0.81
Clinical trial with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother Rep (1972) 0.81
Abolished production of interferon by leucocytes of patients with the acquired cytogenetic abnormalities 5q -- or -- 5 in secondary and de-novo acute non-lymphocytic leukaemia. Br J Haematol (1980) 0.80
Anticoagulant treatment of acute coronary thrombosis. Acta Med Scand (1969) 0.80
Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. Cancer Treat Rep (1982) 0.80
Immunohistochemical identification of lymphocyte subsets and accessory cells in human hyperplastic lymph nodes. The functional significance of the compartmentalization of lymphoid tissue. Scand J Haematol (1984) 0.80
Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B. J Clin Oncol (1986) 0.80
Prognostic significance of tumour burden in Hodgkin's disease PS I and II. Scand J Haematol (1986) 0.79
Metabolic studies in man with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother Rep (1972) 0.79
Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res (1973) 0.79
Cefotaxime versus ampicillin, methicillin and netilmicin in combination for treatment of febrile episodes in patients with haematologic malignancy. Acta Med Scand (1983) 0.78
Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial. Cancer Treat Rep (1984) 0.78
Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer (1993) 0.78
Clinical experience with bacteraemia in patients with leukaemia and allied neoplastic diseases. Chemotherapy (1978) 0.78
Changes over the course of time in histological subclassification of Hodgkin's disease in Denmark. Dan Med Bull (1991) 0.78
Anthracycline resistance. Acta Oncol (1989) 0.78
Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells. Br J Cancer (1993) 0.78
In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues. Biochem Pharmacol (1990) 0.77
The liver in Hodgkin's disease--II. Histopathologic findings. Eur J Cancer Clin Oncol (1982) 0.77
Development and application of a sensitive radioimmunoassay for human granulocyte-macrophage colony-stimulating factor able to measure normal concentrations in blood. Exp Hematol (1993) 0.77
Therapeutic implications of mediastinal involvement in advanced Hodgkin's disease. Scand J Haematol (1985) 0.77
In vivo kinetics of 111indium-labelled autologous granulocytes following i.v. administration of granulocyte-macrophage colony-stimulating factor (GM-CSF). Eur J Haematol (1992) 0.77
Clonal evolution demonstrated by flow cytometric DNA analysis of a human colonic carcinoma grown in nude mice. Exp Cell Biol (1982) 0.77
A simplified working formulation of non-Hodgkin's lymphomas based on quantifiable histologic criteria. Cancer (1989) 0.77
Modulation of neutrophil and monocyte function by recombinant human granulocyte macrophage colony-stimulating factor in patients with lymphoma. Eur J Clin Invest (1991) 0.77
Human immunodeficiency virus (HIV) associated non-Hodgkin's lymphomas in Denmark: report of three cases. Eur J Haematol (1987) 0.77
Phase I trial of a new form of an oral administration of VP-16-213. Cancer Treat Rep (1979) 0.77
Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the Cancer and Leukemia Group B. Cancer Treat Rep (1977) 0.77
Cross resistance and cellular uptake of 4'-O-methyldoxorubicin in experimental tumors with acquired resistance to doxorubicin. Cancer Chemother Pharmacol (1981) 0.76
Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B. Cancer (1980) 0.76
Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213). Cancer Chemother Rep (1972) 0.76
Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma. Cancer (1978) 0.76
Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B. Cancer (1981) 0.76
Cefotaxime monotherapy in septicemic patients with hematological malignancies. Clin Ther (1986) 0.75
Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy. Br J Cancer (1987) 0.75
Phase II trial of cis-dichlorodiammineplatinum(II) in advanced malignant lymphoma and small cell lung cancer: preliminary results. Cancer Treat Rep (1980) 0.75
Effect of methanol extraction residue of Bacillus Calmette-Guerin in advanced Hodgkin's disease. Cancer (1982) 0.75
Mitoxantrone in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma (1992) 0.75
S-phase induction by interleukin-6 followed by chemotherapy in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Leuk Lymphoma (1999) 0.75
[Campath-1H--a monoclonal antibody for treatment of non-Hodgkin's and chronic lymphatic leukemia]. Ugeskr Laeger (1997) 0.75
[Rubidomycin-daunomycin, a new antibiotic with antineoplastic effect]. Nord Med (1968) 0.75
Ornithine carbamoyl transferase activity in serum. Preliminary experience with a non-isotopic method suitable for routine clinical analysis. Scand J Clin Lab Invest Suppl (1967) 0.75
Comparative studies on spironolactone (Aldactone) and chlorthalidone (Hygroton) in the treatment of arterial hypertension. Acta Med Scand (1966) 0.75
Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden. Eur J Haematol (1988) 0.75
[Ultrasound and lymphography in malignant lymphoma. Comparison with consideration to staging]. Ugeskr Laeger (1994) 0.75
[Lactate dehydrogenase isoenzyme patterns in serum in hematologic and neoplastic diseases]. Nord Med (1968) 0.75
Effects of interleukin-3 following chemotherapy of non-Hodgkin's lymphoma. A prospective, controlled phase I/II study. Eur J Haematol (1995) 0.75
Hodgkin's disease and age. Eur J Haematol (1989) 0.75
S-phase induction by interleukin-6 followed by chemotherapy in patients with refractory multiple myeloma. Leuk Res (1998) 0.75
[Serum-lactate dehydrogenase isoenzymes in myocardial and hepatic disease]. Nord Med (1967) 0.75
[Drug treatment of neoplastic diseases]. Nord Med (1966) 0.75
Studies on the antineoplastic effect of vanadium salts. Acta Chir Scand Suppl (1965) 0.75
Comparative studies on the diuretic and biochemical effects of prednisone and spironolactone in hepatic cirrhosis. Acta Med Scand (1966) 0.75
Patterns of lactic acid dehydrogenase isoenzymes in normal and malignant human tissues. Eur J Cancer (1965) 0.75
The in vivo effects of interleukin-3 on histamine levels in non-Hodgkin's lymphoma patients. Pharmacol Toxicol (1997) 0.75
Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study. J Clin Oncol (1992) 0.75
Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol (1995) 0.75
[Allopurinol treatment of hyperuricemia]. Nord Med (1967) 0.75
[Malignant hematologic diseases. Diagnosis and treatment. A clearing report]. Ugeskr Laeger (1991) 0.75
Recombinant human interleukin-3: pharmacokinetics after intravenous and subcutaneous bolus injection and effects on granulocyte kinetics. Br J Haematol (1994) 0.75